guest ::
| Home > Publications database > Prognostic relevance of miRNA-155 methylation in anaplastic glioma. > print |
| Home > Publications database > Prognostic relevance of miRNA-155 methylation in anaplastic glioma. > print |
| 001 | 130493 | ||
| 005 | 20240228143438.0 | ||
| 024 | 7 | _ | |a 10.18632/oncotarget.13452 |2 doi |
| 024 | 7 | _ | |a pmid:27880937 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC5347671 |2 pmc |
| 024 | 7 | _ | |a altmetric:17885516 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-05572 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Schliesser, Maximilian |0 P:(DE-He78)2970cb1f38e9cb41d755455acd14893e |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Prognostic relevance of miRNA-155 methylation in anaplastic glioma. |
| 260 | _ | _ | |a [S.l.] |c 2016 |b Impact Journals LLC |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1524811474_6707 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The outcome of patients with anaplastic gliomas varies considerably depending on single molecular markers, such as mutations of the isocitrate dehydrogenase (IDH) genes, as well as molecular classifications based on epigenetic or genetic profiles. Remarkably, 98% of the RNA within a cell is not translated into proteins. Of those, especially microRNAs (miRNAs) have been shown not only to have a major influence on physiologic processes but also to be deregulated and prognostic in malignancies.To find novel survival markers and treatment options we performed unbiased DNA methylation screens that revealed 12 putative miRNA promoter regions with differential DNA methylation in anaplastic gliomas. Methylation of these candidate regions was validated in different independent patient cohorts revealing a set of miRNA promoter regions with prognostic relevance across data sets. Of those, miR-155 promoter methylation and miR-155 expression were negatively correlated and especially the methylation showed superior correlation with patient survival compared to established biomarkers.Functional examinations in malignant glioma cells further cemented the relevance of miR-155 for tumor cell viability with transient and stable modifications indicating an onco-miRNA activity. MiR-155 also conferred resistance towards alkylating temozolomide and radiotherapy as consequence of nuclear factor (NF)κB activation.Preconditioning glioma cells with an NFκB inhibitor reduced therapy resistance of miR-155 overexpressing cells. These cells resembled tumors with a low methylation of the miR-155 promoter and thus mir-155 or NFκB inhibition may provide treatment options with a special focus on patients with IDH wild type tumors. |
| 536 | _ | _ | |a 317 - Translational cancer research (POF3-317) |0 G:(DE-HGF)POF3-317 |c POF3-317 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Claus, Rainer |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Hielscher, Thomas |0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |b 2 |u dkfz |
| 700 | 1 | _ | |a Grimm, Christiane |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Weichenhan, Dieter |0 P:(DE-He78)ff4024f7bc236e7897d9c18ee19c451f |b 4 |u dkfz |
| 700 | 1 | _ | |a Blaes, Jonas |0 P:(DE-He78)e9a2788d72412f2864cee1ff0cd6b3ca |b 5 |u dkfz |
| 700 | 1 | _ | |a Wiestler, Benedikt Paul Otmar |0 P:(DE-He78)2d0c564eca775a62ff86225f7717af12 |b 6 |u dkfz |
| 700 | 1 | _ | |a Hau, Peter |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Schramm, Johannes |b 8 |
| 700 | 1 | _ | |a Sahm, Felix |0 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88 |b 9 |u dkfz |
| 700 | 1 | _ | |a Weiß, Elisa K |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Weiler, Markus |b 11 |
| 700 | 1 | _ | |a Baer, Constance |b 12 |
| 700 | 1 | _ | |a Schmidt-Graf, Friederike |b 13 |
| 700 | 1 | _ | |a Schackert, Gabriele |b 14 |
| 700 | 1 | _ | |a Westphal, Manfred |b 15 |
| 700 | 1 | _ | |a Hertenstein, Anne |0 P:(DE-He78)82e0de3d5aa5330bb2470e74c48773ca |b 16 |u dkfz |
| 700 | 1 | _ | |a Roth, Patrick |b 17 |
| 700 | 1 | _ | |a Galldiks, Norbert |b 18 |
| 700 | 1 | _ | |a Hartmann, Christian |b 19 |
| 700 | 1 | _ | |a Pietsch, Torsten |b 20 |
| 700 | 1 | _ | |a Felsberg, Joerg |b 21 |
| 700 | 1 | _ | |a Reifenberger, Guido |b 22 |
| 700 | 1 | _ | |a Sabel, Michael Christoph |b 23 |
| 700 | 1 | _ | |a Winkler, Frank |0 P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b |b 24 |u dkfz |
| 700 | 1 | _ | |a von Deimling, Andreas |0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144 |b 25 |u dkfz |
| 700 | 1 | _ | |a Meisner, Christoph |b 26 |
| 700 | 1 | _ | |a Vajkoczy, Peter |b 27 |
| 700 | 1 | _ | |a Platten, Michael |0 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5 |b 28 |u dkfz |
| 700 | 1 | _ | |a Weller, Michael |b 29 |
| 700 | 1 | _ | |a Plass, Christoph |0 P:(DE-He78)4301875630bc997edf491c694ae1f8a9 |b 30 |u dkfz |
| 700 | 1 | _ | |a Wick, Wolfgang |0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee |b 31 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.18632/oncotarget.13452 |g Vol. 7, no. 50 |0 PERI:(DE-600)2560162-3 |n 50 |p 82028-82045 |t OncoTarget |v 7 |y 2016 |x 1949-2553 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:130493 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)2970cb1f38e9cb41d755455acd14893e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)ff4024f7bc236e7897d9c18ee19c451f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)e9a2788d72412f2864cee1ff0cd6b3ca |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)2d0c564eca775a62ff86225f7717af12 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)82e0de3d5aa5330bb2470e74c48773ca |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 24 |6 P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 25 |6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 28 |6 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 30 |6 P:(DE-He78)4301875630bc997edf491c694ae1f8a9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 31 |6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-317 |2 G:(DE-HGF)POF3-300 |v Translational cancer research |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ONCOTARGET : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ONCOTARGET : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)G160-20160331 |k G160 |l Neuroimmunologie und Hirntumorimmunologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)G370-20160331 |k G370 |l KKE Neuroonkologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)G380-20160331 |k G380 |l KKE Neuropathologie |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)C010-20160331 |k C010 |l Epigenomik und Krebsrisikofaktoren |x 3 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 4 |
| 920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 5 |
| 920 | 1 | _ | |0 I:(DE-He78)L401-20160331 |k L401 |l DKTK Essen |x 6 |
| 920 | 1 | _ | |0 I:(DE-He78)L301-20160331 |k L301 |l DKTK Dresden |x 7 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G160-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G370-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G380-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C010-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L101-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L401-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L301-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|